Background: Malignant melanoma is a highly aggressive neoplastic disease whose incidence is increasing rapidly. In recent years, the use of interferon α (IFNα) has become the most established adjuvant immunotherapy for melanoma of advanced stage. IFNα is a potent inhibitor of melanoma cell proliferation, and the signal transducer and activator of transcription STAT1 is crucial for its antiproliferative action. Although advanced melanomas clinically resistant to IFNα are frequently characterized by inefficient STAT1 signaling, the mechanisms underlying advanced-stage interferon resistance are poorly understood. 
Introduction
Over the past few decades, the incidence of malignant melanoma has increased at a rate that exceeds that of any other solid tumor. With a limited efficiency of chemotherapy, the use of interferon α (IFNα) has become the most established adjuvant immunotherapy for melanoma of advanced stage. However, the results of multiple clinical trials are controversial and difficult to interpret partly because of a great heterogeneity between the parameters of the trials [1, 2] .
IFNα mediates its effects through activation of the janus kinases JAK1 and TYK2, which in turn phosphorylate and activate the signal transducers and activators of transcription: STAT1, STAT2, and STAT3. Activation of these latent transcription factors results in the formation of STAT homo-and heterodimers, their nuclear translocation, and trans-activation of the interferonstimulated genes (ISGs) [3] . ISGs are characterized by the presence of γ activating sequences (GAS) and/or interferon response elements (ISRE) in their promoters. GAS elements are the targets for STAT homo-or heterodimers, whereas ISRE sites are bound by the interferonstimulated gene factor 3 (ISGF3) in response to IFNα [4] . ISGF3 is a trimeric complex and consists of STAT1, STAT2, and the interferon-stimulated gene factor 3γ (p48/ISGF3γ/IRF-9). Although IFNα activates gene expression through GAS elements, the major part of the IFNα-induced gene expression is brought about by ISGF3's binding to ISRE sites [5] . The essential role of STAT1 in the mediation of an IFNα response (and, in general, interferon signaling) is seen in STAT1 (−/−) mice, which are unresponsive to interferons but remain responsive to other cytokines [6] .
In addition to immunomodulatory activity, IFNα has a direct growth-inhibiting effect on melanoma cells [7, 8] . However, cell lines originating from melanoma of advanced stage are frequently unresponsive to the growthinhibiting effect of IFNα. Such interferon-resistant cells often show defective JAK-STAT signaling, which correlates either with a significant reduction in the level of STAT1 protein or inefficient phosphorylation of STAT1 [7, 9, 10] . However, whereas inefficient STAT1 phosphorylation in response to IFNα and reduced STAT1 levels have also been observed in melanoma patients [9, 11, 12] , other studies describe only slight variations in STAT1 expression levels in melanoma biopsies and no loss of function in interferon-resistant cell lines [13, 14] . Thus, the mechanism underlying the cellular IFNα resistance seems to be complex. For the successful application of IFNα in melanoma therapy, it is, however, important to understand the specific function of this interferon in melanoma cells.
It is noteworthy that stimulation of interferon receptors can also lead to the activation of STAT5 [15] [16] [17] . In contrast to STAT1, STAT5 is involved in mitogenic as well as in antiapoptotic signaling [6] . STAT5 is constitutively active in a variety of transformed cells, which include Xiphophorus melanoma cells [18] [19] [20] . Although this suggests an involvement of STAT5 in promoting oncogenesis in pigment cells, nothing is known about its functional role in human melanoma development.
To investigate whether STAT5 plays a role in the development of melanoma, we analyzed its expression in melanoma biopsies and several human melanoma cell lines. STAT5 was found to be overexpressed in IFNα-resistant cell lines and in situ in advanced melanoma lesions. Overexpression of STAT5 in IFNα-sensitive cells revealed that STAT5 can counteract the STAT1-mediated IFNα response by upregulating the cytokine inhibitor CIS. Furthermore, depletion of STAT5 from IFNα-resistant cells by RNA interference (RNAi) resulted in enhanced sensitivity toward IFNα-induced growth inhibition. In summary, our findings strongly suggest a role for STAT5 in the frequently found clinical resistance of advanced melanoma to interferon.
Results

STAT5 Expression in Melanocytic Lesions Correlates with Tumor Progression
In human skin, STAT5 expression was detected specifically in melanocytes located in the basal membrane of the epidermis (STAT5 FITC, Figure 1A) , where it colocalized with the melanocyte differentiation antigen MART-1. No significant expression of the STAT protein was seen in surrounding keratinocytes, and this was confirmed in the keratinocyte cell line HaCat ( Figure  1B ). Both STAT5a and STAT5b were expressed in primary human melanocytes (mel 1043 and mel 775) to a level similar to that found in the human primary melanoma cell line IFB, whereas STAT5 expression was increased in Mel19 metastatic melanoma cells ( Figure  1B ). STAT1 was expressed in melanoma cells, in melanocytes, and in keratinocytes ( Figure 1B) , underlining the specificity of STAT5 expression in pigment cells of the epidermis.
Staining of melanocytic skin lesions with anti-STAT5 detected the expression of STAT5 in both benign and neoplastic melanocytic lesions ( Figures 1C and 1D) . Because STAT5 expression is not restricted to melanocytic cells but can also be seen in leukocytes, double staining for STAT5 and the melanocyte differentiation antigen MART-1 was performed. This confirmed that the majority of STAT5-expressing cells within the tested lesions were of melanocytic origin ( Figure 1D ). Strikingly, the number of STAT5-expressing cells was significantly elevated in neoplastic lesions compared to benign nevi ( Figures 1C and 1D , p % 0.001). Analysis of the cellular distribution in MART-1-positive cells revealed that although the relative amount of cytoplasmic STAT5 to nuclear-localized STAT5 did not significantly change during tumor progression, the absolute number of cells showing intranuclear localization increased from benign to neoplastic and primary to metastatic lesions ( Figure 1D ).
STAT5 Expression Is Enhanced in InterferonResistant Melanoma Cells
Analysis of STAT5 protein levels in various melanoma cell lines showed a significantly enhanced expression in D10, MM96, Mel19, and WM164 cells (Figure 2A) . Two of the STAT5-overexpressing cell lines, D10 and MM96, are known to be resistant toward interferoninduced growth inhibition [7, 9] , and our analysis revealed a noticeable correlation of STAT5 overexpression with IFNα resistance (Figures 2A and 2B) . Notably, STAT1 was expressed in all cell lines regardless of their reactivity toward IFNα, and although slight differences in the protein level of STAT1, as well as those of STAT2 and STAT3 were observed, they did not strictly correlate with interferon resistance (Figures 2A and 2B) .
In all interferon-resistant cell lines, IFNα stimulation resulted in phosphorylation of JAK1 and TYK2 ( Figure  2C ), indicating that the receptors are active. However, whereas STAT1 became strongly phosphorylated in response to IFNα in all sensitive cell lines and in human primary melanocytes, the STAT1 phosphorylation level was reduced or completely abolished in three (MM96, Mel19, and WM164) of four resistant cell lines ( Figure 2D ).
Because interferon-resistant cell lines appear to overexpress STAT5, we asked both whether STAT5 might interfere with IFNα induced STAT1 activation and whether STAT5 plays a significant role in IFNα signaling in melanoma cells.
Activation of STAT1 Is Required for an Efficient IFN␣ Response in Melanoma Cells
For our further experiments, we chose A375 cells because they showed the highest IFNα sensitivity in our hands. Stimulation of A375 cells with IFNα resulted in phosphorylation of STAT1 (see Figure 2D ) and nuclear translocation ( Figure 3A) . IFNα also induced binding of the STAT1-containing IGSF3 complex to ISRE sequences ( Figure 3B ). Already 30 min after addition of IFNα, all three components of IGSF3 were found to bind to the ISRE sequence ( Figure 3B ). However, after 22 hr IFNα stimulation, the amount of ISRE bound STAT1, STAT2, and p48 was considerably enhanced. This delayed increase correlated with the trans-activation of an ISRE-containing promoter, which was weak (1.3-fold) after 3 hr but much stronger (7.3-fold) after 22 hr ( Figure  3C ) and was also reflected in the induction of hPNPase old-35 ( Figure 3D ), an interferon-inducible gene whose expression is regulated through an ISRE site in melanoma cells [21] .
The importance of STAT1 for IFNα signaling was seen in A375 cells expressing a dominant-negative STAT1, in which tyrosine 701 is mutated to phenylalanine [22] and which therefore shows no significant tyrosine phosphorylation in response to IFNα ( Figure 3E Figure 5F ). Strikingly, also wild-type STAT5A had a significant effect on the interferon-mediated growth inhibition (Figure 5F ), indicating that STAT5 overexpression alone is sufficient to antagonize the IFNα response. Also, over- Because STAT1 is essential for the mediation of antiproliferative effects brought about by interferons, it is not surprising that deficient STAT1 activation is correlated with interferon resistance in melanoma [11, 12] .
We present here several lines of evidence for a role of STAT5 in melanoma development and its involvement in interferon resistance. We have shown that STAT5 is overexpressed in cell lines derived from advanced melanoma and that nuclear-localized STAT5 increased with tumor progression in melanoma biopsies. We also found that STAT5 was localized in the cytoplasm in melanocytes and melanoma cells derived from a primary melanoma (IFB and A375 cells), whereas predominantly nuclear localization was seen in all other melanoma cell lines ( Figure S2 and data not shown) . Because nuclear translocation of STATs is implicated in their cellular activation, this suggests constitutive activation of STAT5 in malignant melanoma. However, future studies involving analysis of STAT5 phosphorylation are required to fully establish the state of STAT5 activation in melanoma.
We found that STAT5 overexpression correlated with IFNα resistance in melanoma cell lines. Significantly, ectopic overexpression of STAT51*6 as well as wildtype STAT5 severely reduced the ability of IFNα to inhibit proliferation in an IFNα-sensitive cell line. Moreover, depletion of STAT5 in IFNα-resistant cells dramatically enhanced the responsiveness to IFNα. This strongly supports the notion that deregulation of STAT5 activity is likely to make a significant contribution to the acquisition of IFNα resistance. STAT1 activation is crucial for IFNα-induced growth inhibition in melanoma cells [7, 9] but was found to be inhibited by the overexpression of STAT51*6. Because STAT1 is an essential component of ISGF3, the transcription factor that binds to the ISRE in interferoninduced genes [4] , ISRE-dependent transcription was strongly suppressed in STAT51*6-expressing cells. We found that in melanoma cells, ISGF3-mediated transcription is a late event that would require sustained STAT1 activation. However, activation of STAT5 resulted in abrogation of sustained STAT1 activation. This was sufficient to affect ISGF3-driven transcription as seen in the suppression of hPNPase old-35 expression. Notably, enhanced hPNPase old-35 expression strongly inhibits melanoma cell growth [26] , and the suppression of hPNPase old-35 levels will counteract this antiproliferative effect.
Although STAT51*6 became activated by IFNα immediately after receptor stimulation, its inhibitory effect on STAT1 became apparent only in a later phase of activation, suggesting the involvement of the suppressor of cytokine signaling (SOCS/CIS) factors. A mutual regulation of STATs on the level of SOCS/CIS factors has been found in a variety of cell systems where the suppression of STAT1 tyrosine phosphorylation blocks interferoninduced cellular responses [27, 28] . In STAT51*6-overexpressing cells, impaired STAT1 activation was correlated with a reduced SOCS3 (CIS3) expression and a strongly enhanced CIS (CIS1) expression. We demonstrate here that overexpression of CIS contributes to the effect of STAT5 and leads to a significant suppression of IFNα-induced transcription. Furthermore, overexpression of CIS in IFNα-senstitive cells reduced the interferon response of the cells. This suggests a new role for CIS in the acquisition of interferon resistance in melanoma. However, the effect brought about by CIS accounted only for 50% of the effect caused by STAT5, which suggests that the STAT5-induced IFNα resistance involves the activation of additional factors.
Although both CIS and SOCS3 inhibit cytokine-induced signaling, they differ in the way they act. SOCS3 affects the activity of JAK kinases, and CIS inhibits the binding of STATs to the activated tyrosine-phosphorylated receptor [29] . Interestingly, we and others have demonstrated that STAT5, but neither STAT1 nor STAT3, can become activated independently from receptor phosphorylation [30, 31] . On the other hand, activation of STAT1 by the IFN receptor is strictly dependent on receptor phosphorylation [32] . Thus, STAT1 activation might be inhibited by overexpression of CIS, whereas STAT5 could still become activated by the receptor.
Another possibility by which overexpression of STAT5 could affect the activation of STAT1 could be competition of STAT5 with STAT1 for activation by the receptor. Accordingly, in cells that overexpress STAT51*6, STAT5 phosphorylation is much stronger (see Figures S1) and STAT1 activation is decreased. Also, when STAT5 expression was lowered by RNAi, its activation was reduced and STAT1 activation was increased (see Figure  6 ). However, the most striking differences in STAT1 activation between interferon-resistant and -sensitive cells were observed at later time points (3-6 hr), suggesting that reduced STAT1 activity is rather due to enhanced STAT5 downstream signaling than to overexpressed STAT5 preventing STAT1 activation by the receptor through competition. Furthermore, we found that overexpression of either wild-type or dominant-negative STAT1 had no significant effect on the activation of STAT5 (not shown). Similarly, no increase in interferoninduced STAT5 activation was found in T cells from STAT1 (−/−) mice when compared to normal T cells [33] , and this points to no influence of STAT1 expression levels on STAT5 activation by the interferon receptor. Together, these data suggest that the effects we observed are not due to competition at the receptor level, but further studies are required to fully address this issue.
Conclusions
The data presented here show that in melanoma cells, STAT1 and STAT5 exhibit a functional antagonism; whereas STAT5 promotes cell growth and protects the cells from the inhibitory effect of IFNα, STAT1 contributes to growth inhibition. Thus, a tight regulation of STAT activation and signaling seems to be a critical step in the cytokine-mediated growth control of melanoma cells. Our findings suggests that loss of STAT1 activity but gain of STAT5 activity can lead to an imbalance in this regulation and enables melanoma cells to overcome cytokine-mediated antiproliferative signaling, thus contributing to melanoma development and progression. 
Preparation of Cell Extracts and STAT5 DNA Binding
Cell extracts were prepared by four freeze-thaw cycles in low salt lysis buffer (20 mM HEPES, pH 7.9, 20% glycerol, 100 mM NaCl, 50 mM KCl, 1 mM EDTA, 1 mM DTT, 1 mM PMSF, 1 mM Na 3 VO 4 , 10 g/ml leupeptin, and 10 g/ml aprotinin). The cleared supernatant was incubated with M280-Streptavidin Dynabeads (Dynal) carrying either multiple ISRE (5#-GATCCAGGCTCCCGGGAAAGCGAA ACCTAAACAGTGGCGC-3#) or GAS elements (5#-GATCAGATTTT AGGAAATCAATCC-3#) or a mutated GAS sequence (5#-GATCA GATTTATTTTAATTCAATCC-3#). Bound proteins were eluted and analyzed by western blotting. 
Transfections and Luciferase Reporter Assays
RT-PCR Analysis
RNA was isolated with TRIZOL reagent (Invitrogen). First-strand cDNA synthesis was done with 1 g total RNA and random hexanucleotides. The respective genes were amplified with a number of cycles, where amplification was still linear and analyzed on an agarose gel. The primers were the following: for cis, 5#-CTGCTGTG CATAGCCAAGACGTTC-3# and 5#-CAGAGTTGGAAGGGGTACTGT CGG-3#; for socs3, 5#-GGTCACCCACAGCAAGTTTCC-3# and 5#-GTCCAGGAACTCCCGAATGGG-3#; for hPNPase old-35 , 5#-AAGA GAACTTGGGCATGGTG-3# and 5#-TTTGCCACTGAAGCTTGTTG-3#; and for gapdh 5#-CGGAGTCAACGGATTTGGTCGTAT-3# and 5#-AGCCTTCTCCATGGTGGTGAAGAC-3#. 
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